Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Antibodies Licensed for Multi-Target Immunotherapies

MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies

Patent Awarded for Nanoparticle Drug, Cannabis Delivery

A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments. . . . → Read More: Patent Awarded for Nanoparticle Drug, Cannabis Delivery

Novartis Licenses Biomaterial for Cancer Immunotherapy

Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer. . . . → Read More: Novartis Licenses Biomaterial for Cancer Immunotherapy

Smartphone App, Device Shown to Measure Blood Pressure

A smartphone-based system and app were shown in a pilot study with human subjects to measure a person’s blood pressure with about the same accuracy as some cuff devices normally used to gauge blood pressure. . . . → Read More: Smartphone App, Device Shown to Measure Blood Pressure

Evotec Acquiring Sanofi Infectious Disease Portfolio

Drug discovery company Evotec AG is licensing 10 infectious disease R&D programs and their 100 employees from drug maker Sanofi, and opening new labs for this work in Lyon, France. . . . → Read More: Evotec Acquiring Sanofi Infectious Disease Portfolio

Company Formed to Develop Cancer Cell Therapies

The MD Anderson Cancer Center in Houston is starting Optera Therapeutics Corp., a new company to commercialize its research on treating cancer with a patients’ own immune system cells. . . . → Read More: Company Formed to Develop Cancer Cell Therapies

Trial Shows Reduction in Huntington Disease Protein

First results from a clinical trial show an experimental therapy reduces production of a protein damaging nerve cells in people with Huntington disease. . . . → Read More: Trial Shows Reduction in Huntington Disease Protein

Start-Up Developing Blood-Brain Barrier Treatments

A medical school professor in Singapore is starting a biotechnology company to discover and develop new drugs for neurological disorders based on his research with mechanisms for crossing the blood-brain barrier. . . . → Read More: Start-Up Developing Blood-Brain Barrier Treatments

Techniques Devised to Boost Gene Therapy Success

An engineering team at Washington University in St. Louis is developing mechanical and electronic processes to improve the success of inserting large, complex therapeutic molecules like DNA into cells. . . . → Read More: Techniques Devised to Boost Gene Therapy Success

Pharma, Biotech Partner on Neuro Therapies in $1.1B Deal

Voyager Therapeutics, a developer of gene therapies for neurological disorders, is collaborating with drug maker AbbVie on treatments for diseases resulting from the build-up of damaging proteins in the brain, as in Alzheimer’s disease. . . . → Read More: Pharma, Biotech Partner on Neuro Therapies in $1.1B Deal